The human immune system is the product of hundreds of millions of years of evolution. It can recognize and neutralize an almost limitless variety of pathogens, remember invaders it has seen before, and coordinate an elaborate cascade of cellular defenses. It is also, by evolutionary standards, agonizingly slow.
Consider the mathematics of the arms race. A typical human generation spans roughly 30 years. A typical bacterial generation spans 20 minutes. In the time it takes a human population to produce a single new generation, a bacterial population can produce more than 700,000. For RNA viruses, the gap is even wider. Influenza evolves so quickly that the vaccine must be reformulated every year. SARS-CoV-2 produced a cascade of immune-evading variants within months of entering the human population. The vertebrate immune system is a masterpiece, but it competes against opponents that run through millennia of evolutionary experimentation in a single flu season.
This disparity sits at the heart of a growing field called evolutionary medicine, and it has produced one of the most contentious debates in infectious disease treatment today: what to do about fever.
The Fever Paradox
Fever is the most common physiological response to infection across the animal kingdom. From fish and reptiles to mammals and birds, virtually every vertebrate raises its body temperature in response to pathogens. The consistency of the response across such a vast evolutionary distance strongly suggests it is an adaptation, not a side effect.
Evolutionary biologist Paul Ewald has argued this point for decades. Fever, in his view, is an evolved defense mechanism. Raising body temperature creates an inhospitable environment for many pathogens, inhibiting their replication while enhancing immune cell activity. Interfering with this response with antipyretics such as ibuprofen or acetaminophen, Ewald contends, may prolong illness and increase the severity of infection. The logic is straightforward: if the body evolved fever to fight infection, suppressing it is working against your own defenses.
Legal scholar Owen D. Jones, in his 2026 book Force of Nature, takes up Ewald’s argument and extends it into a broader case for evolutionary thinking in medicine. Jones argues that the medical establishment has been too quick to treat fever as a symptom to be eliminated rather than a defense to be respected. The book calls for a fundamental rethinking of how clinicians approach the febrile patient, suggesting that unless a fever reaches dangerously high levels (above 40 degrees Celsius, or 104 degrees Fahrenheit), it should generally be allowed to run its course.
It is a compelling argument. It may also be dangerously incomplete.
When Fever Helps the Wrong Side
Jonathan R. Goodman, a researcher at the University of Cambridge, reviewed Force of Nature for Nature in July 2026. In his assessment, the blanket rule against fever suppression commits the same error it accuses conventional medicine of: it assumes one size fits all.
The problem, Goodman points out, is that pathogens evolve fast. A bacterium or virus that has been infecting human hosts for thousands of generations has had ample evolutionary time to adapt to the conditions it encounters there, including fever.
Some of the deadliest infections in human history thrive in febrile environments. The bacteria that cause typhoid fever reproduce more efficiently at elevated temperatures. The viruses that cause dengue hemorrhagic fever trigger a cytokine storm partly driven by the host’s temperature response. In these cases, suppressing fever may not weaken the immune response. It may instead remove an advantage the pathogen has evolved to exploit.
The evolutionary logic cuts both ways. A pathogen that has spent most of its history in species with lower body temperatures, or that has only recently crossed into humans, may be genuinely impaired by fever. A pathogen that has co-evolved with humans for millennia may have already solved the fever problem. It may have evolved to expect it, to use it, or even to trigger it for its own benefit.
This is not a theoretical concern. The clinical literature contains decades of conflicting results on fever suppression. Some studies show that antipyretics prolong viral shedding in respiratory infections. Others show no effect or even benefit. The confusion may arise because the studies treat fever as a single phenomenon rather than recognizing that its effect depends on which pathogen is present.
The Genomic Compass
Goodman proposes a solution that would have been science fiction a generation ago: use genomic sequencing to determine, in real time, whether the infecting pathogen thrives at febrile temperatures. The idea is to read the pathogen’s evolutionary history from its genome. If sequencing reveals that the pathogen’s ancestors spent millions of years evolving in febrile hosts, then fever may be working against the patient. If the pathogen is a relative newcomer to warm-blooded hosts, fever may be an effective defense.
The technology to do this already exists. Pathogen genomic sequencing is increasingly available in clinical settings, particularly for identifying drug-resistant strains of tuberculosis, tracking hospital outbreaks, and diagnosing unusual infections. Extending the analysis to include the pathogen’s thermal adaptation profile would require new reference databases and clinical validation, but the core infrastructure is in place.
The approach would turn fever management into a form of personalized medicine, guided not by a blanket rule but by the specific evolutionary relationship between patient and pathogen. If the genomic data suggest the pathogen is heat-adapted, the clinician would reduce the fever. If the data suggest it is heat-sensitive, the clinician would let the fever run, monitoring for safety but not intervening.
Evolutionary Medicine Beyond Fever
The fever debate is the most immediately actionable front in a broader intellectual movement. Evolutionary medicine, sometimes called Darwinian medicine, applies the principles of evolutionary biology to questions of health and disease. Its insights are reshaping fields from oncology to agriculture.
In cancer treatment, Robert Gatenby and colleagues have pioneered adaptive therapy. Standard chemotherapy aims to kill as many tumor cells as possible. The problem, from an evolutionary perspective, is that total assault creates ideal conditions for drug-resistant clones to take over. Kill 99 percent of a tumor, and the surviving 1 percent faces no competition. The resistant cells multiply unchecked. Adaptive therapy takes the opposite approach: use just enough chemotherapy to keep the tumor in check while preserving drug-sensitive cells to suppress resistant ones. A 2009 study by Gatenby’s group in Cancer Research demonstrated that this evolution-informed strategy can extend disease control dramatically compared to standard dosing, though it remains experimental.
Antimicrobial resistance is another domain where evolutionary thinking has moved from academic interest to clinical necessity. Every use of an antibiotic imposes selection pressure for resistance. Evolutionary models can predict which drug combinations will minimize the emergence of resistance, how long a given antibiotic should be used, and when rotating between drug classes is most effective. The World Health Organization has recognized antimicrobial resistance as one of the top global public health threats, and evolutionary biology offers some of the most promising tools for managing it.
Even agriculture is being rethought through an evolutionary lens. Monoculture cropping systems, which plant vast areas with genetically identical crops, create ideal conditions for pathogens to evolve resistance, much like total chemotherapy creates conditions for resistant cancer clones. Evolution-informed agricultural strategies include planting mixed varieties, rotating crops, and maintaining refuges of non-resistant plants to slow the spread of resistance genes.
The Path Forward
The fever debate illustrates a broader principle that evolutionary medicine is only beginning to establish in clinical practice: biological systems are shaped by history, and history matters for treatment. The question is not whether fever is good or bad. The question is whether the particular pathogen a patient is fighting evolved in a world where fever existed.
Answering that question requires more than clinical intuition. It requires genomic data, evolutionary analysis, and a willingness to abandon blanket rules in favor of context-specific decision making. The technology is nearly ready. The conceptual shift is harder.
Force of Nature, and the debate it has provoked, represent a maturing of evolutionary medicine. The field is moving past the stage of pointing out that evolution matters and toward the harder work of specifying how it should change clinical practice. The fever debate is the most visible example, but it will not be the last. As genomic sequencing becomes cheaper and faster, and as evolutionary analysis becomes integrated into routine diagnostics, the question may shift from whether evolution belongs in medicine to why it took so long to get there.
The pathogens have been evolving all along. Medicine, at last, is beginning to catch up.